These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34074484)

  • 1. A comparison of the safety and effectiveness of prasugrel and clopidogrel in younger population undergoing percutaneous coronary intervention: A retrospective study using a Japanese claims database.
    Hagiwara H; Fukuta H; Hashimoto H; Niimura T; Zamami Y; Ishizawa K; Kamiya T; Ohte N
    J Cardiol; 2021 Mar; 77(3):285-291. PubMed ID: 34074484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
    Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases.
    Hagiwara H; Fukuta H; Niimura T; Zamami Y; Ishizawa K; Kimura K; Kamiya T; Ohte N
    Int J Med Sci; 2020; 17(6):728-733. PubMed ID: 32218694
    [No Abstract]   [Full Text] [Related]  

  • 5. Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
    Tokimasa S; Kitahara H; Nakayama T; Fujimoto Y; Shiba T; Shikama N; Nameki M; Himi T; Fukushima KI; Kobayashi Y
    Heart Vessels; 2019 Oct; 34(10):1581-1588. PubMed ID: 30944971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Saito S;
    Circ J; 2014; 78(12):2926-34. PubMed ID: 25342212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
    Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
    Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
    Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of bleeding and repeated bleeding events in prasugrel-treated patients: a review of data from the Japanese PRASFIT studies.
    Nishikawa M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    Cardiovasc Interv Ther; 2017 Apr; 32(2):93-105. PubMed ID: 28097639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
    Sawayama Y; Yamamoto T; Tomita Y; Asada K; Yagi N; Fukuyama M; Miyamoto A; Sakai H; Ozawa T; Isono T; Hira D; Terada T; Horie M; Nakagawa Y
    Circ J; 2020 Aug; 84(9):1575-1581. PubMed ID: 32713878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention.
    Koyabu Y; Abe S; Sakuma M; Kanaya T; Obi S; Yoneda S; Toyoda S; Nakajima T; Inoue T
    Intern Med; 2019 Aug; 58(16):2315-2322. PubMed ID: 31118376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
    Bundhun PK; Huang F
    BMC Cardiovasc Disord; 2018 May; 18(1):78. PubMed ID: 29720092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
    Scirica BM; Bergmark BA; Morrow DA; Antman EM; Bonaca MP; Murphy SA; Sabatine MS; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2020 Mar; 75(10):1095-1106. PubMed ID: 32164882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
    J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel.
    Crimi G; Morici N; Ferrario M; Ferri LA; Piatti L; Grosseto D; Cacucci M; Mandurino Mirizzi A; Toso A; Piscione F; De Carlo M; Elia LR; Trimarco B; Bolognese L; Bovenzi FM; De Luca G; Savonitto S; De Servi S
    J Am Heart Assoc; 2019 Jan; 8(2):e010956. PubMed ID: 30636561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.